NCT [ADDRESS_1080741] -Traumatic Stress Disorder  
Protocol  
01 May 2020  
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 1     
 
INVESTIGATIONAL DRUG: NYX-783 
CLINICAL PROTOCOL: NYX-783-[ADDRESS_1080742]-Traumatic Stress Disorder 
 
Sponsor: Aptinyx Inc. 
 
 
 
 
 
 
IND Number: 135011  
This document is a confidential communication from Aptinyx Inc. Acceptance of this document constitutes 
an agreement by [CONTACT_1955][INVESTIGATOR_841](s) that no information contained herein will be published or disclosed 
without prior written approval from Aptinyx Inc., except that this document may be disclosed to 
appropriate Institutional Review Boards (IRBs) under the condition that they are also required to maintain 
confidentiality. 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 2   
INVESTIGATOR SIGNATURE [CONTACT_785710]/her approval of this protocol and provides 
the necessary assurances that this study will be conducted according to all stipulations of the 
protocol as specified in both the clinical and administrative sections, including all statements 
regarding confidentiality. This study will be conducted in compliance with the protocol and all 
applicable regulatory requirements, in accordance with Good Clinical Practices (GCPs), including 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) Guidelines, and in general conformity with the most recent version of the 
Declaration of Helsinki. 
 
Principal Investigator 
 
   
[INVESTIGATOR_785662]-783-2004 Amendment 3 01 May 2020
Aptinyx Confidential 3APPROVAL PAGE:
Aptinyx Inc.
_____________________________ _________________________
 
_____________________________ __________________________

Clinical Protocol NYX-783-[ADDRESS_1080743] OF ABBREVIATIONS.....................................................................................18  
5. INTRODUCTION ......................................................................................................21  
6. STUDY OBJECTIVES AND ENDPOINTS ..............................................................24  
6.1. Criteria for Evaluation ................................................................................................25  
6.1.1.  Efficacy Criteria ..........................................................................................................25  
6.1.2.  Safety Criteria .............................................................................................................25  
6.1.3.  Exploratory Criteria ....................................................................................................26  
7. INVESTIGATIONAL PLAN .....................................................................................27  
7.1. Overall Study Design and Plan: Description ..............................................................[ADDRESS_1080744] Withdrawal Criteria .......................................................................................39  
8.5. Methods of Birth Control............................................................................................40  
9. SCHEDULE OF PROCEDURES ..............................................................................41  
9.1. Screening Period (Day -21 to -7) ................................................................................41  
9.2. Day -7 (±3 days) .........................................................................................................42  
9.3. Stage 1: Day 1 .............................................................................................................42  
9.4. Week 2, Day 14 (±3 days) ..........................................................................................43  
9.5. Stage 2: Week 4, Day 28 (±3 days) ............................................................................43  
9.6. Week 6, Day 42 (±3 days) ..........................................................................................44  
9.7. Week 8, Day 56 (±3 days) ..........................................................................................45  
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 14  9.8. Early Termination Visit ..............................................................................................46  
9.9. Safety Follow-up Visit ([ADDRESS_1080745]-therapy ±3 days) ...............................................47  
10. STUDY TREATMENT ..............................................................................................48  
10.1.  Dosing and Administration .........................................................................................48  
10.2.  Randomization and Blinding ......................................................................................48  
10.3.  Treatment Compliance ................................................................................................49  
10.4.  Concomitant Medications ...........................................................................................49  
10.5.  Study Drug Discontinuation .......................................................................................50  
11. STUDY DRUG MATERIALS AND MANAGEMENT ...........................................51  
11.1.  Study Drug ..................................................................................................................51  
11.2.  Study Drug Packaging and Labeling ..........................................................................51  
11.3.  Study Drug Storage .....................................................................................................51  
11.4.  Study Drug Preparation ..............................................................................................51  
11.5.  Study Drug Accountability .........................................................................................51  
12. STUDY ASSESSMENTS ..........................................................................................53  
12.1.  Psychiatric Rating Scales/Outcome Measures/Test(s) ...............................................53  
12.1.1.  Structured Clinical Interview for DSM-5 (SCID-5-CT) ............................................53  
12.1.2.  SAFER Remote Interview ..........................................................................................53  
12.2.  Clinical Measures .......................................................................................................53  
12.2.1.  Clinician Administered PTSD Scale for DSM-5 (CAPS-5) .......................................53  
12.2.2.  Hospi[INVESTIGATOR_183507] (HADS) .......................................................[ADDRESS_1080746] for DSM-5 (PCL-5) .........................................................................54  
12.2.4.  Clinical Global Impressions-Severity (CGI-S) ...........................................................54  
12.2.5.  Pi[INVESTIGATOR_2272] (PSQI) .......................................................................54  
12.2.6.  Pi[INVESTIGATOR_785663] (PSQI-A) ................................................54  
12.2.7.  55 
12.2.8.  55 
12.2.9.  Dissociative Experiences Scale-II (DES-II) ...............................................................[ADDRESS_1080747] for DSM-5 (LEC-5) ................................................................55  
12.2.11.  Symbol Coding from the Brief Assessment of Cognition (BAC Symbol 
Coding) .......................................................................................................................55  
12.3.  Exploratory Assessments ............................................................................................55  
[IP_ADDRESS].  Pharmacogenomics (PGX) and Biomarkers ...............................................................55  

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 15  12.3.2.  Plasma Concentrations ................................................................................................56  
12.4.  Safety Assessments .....................................................................................................56  
12.4.1.  Demographics and Medical History ...........................................................................56  
12.4.2.  Vital Sign Measurements ............................................................................................56  
12.4.3.  Physical Examination (PE) .........................................................................................56  
12.4.4.  12-lead Electrocardiogram ..........................................................................................57  
12.4.5.  Clinical Laboratory Assessments ...............................................................................57  
12.4.6.  Sheehan Suicidality Tracking Scale (S-STS) .............................................................[ADDRESS_1080748] (DSMB) ..............................................................63  
14. STATISTICAL METHODS .......................................................................................65  
14.1.  General Principles of Statistical Analysis...................................................................65  
14.2.  Sample Size Determination ........................................................................................65  
14.3.  Analysis Populations ..................................................................................................65  
14.4.  Analysis of Efficacy Variables ...................................................................................65  
14.4.1.  Methods of Analysis ...................................................................................................65  
[IP_ADDRESS].  Primary Efficacy Endpoint Analysis ..........................................................................66  
[IP_ADDRESS].  Secondary Efficacy Endpoints Analyses ....................................................................66  
[IP_ADDRESS].  Exploratory Efficacy Endpoints Analyses ..................................................................[ADDRESS_1080749] Disposition .....................................................................................................67  
14.6.  Demographic/Baseline Data .......................................................................................67  
14.6.1.  Demographics and Other Baseline Characteristics .....................................................67  
14.6.2.  Other Baseline Data ....................................................................................................67  
14.7.  Study Drug Exposure ..................................................................................................67  
14.8.  Inclusion/Exclusion Criteria .......................................................................................67  
14.9.  Efficacy Data Listings ................................................................................................68  
14.10.  Analysis of Safety .......................................................................................................68  
14.10.1.  Adverse Events ...........................................................................................................68  
14.10.2.  Clinical Laboratory Tests ...........................................................................................68  
14.10.3.  Electrocardiogram .......................................................................................................68  
14.10.4.  Vital Sign and Weight Measurements ........................................................................68  
14.10.5.  S-STS ..........................................................................................................................68  
14.10.6.  Other Safety Data .......................................................................................................69  
14.11.  Interim Analysis ..........................................................................................................69  
15. ADMINISTRATIVE ..................................................................................................70  
15.1.  Source Documents ......................................................................................................70  
15.2.  Study Monitoring ........................................................................................................70  
15.3.  Case Report Forms .....................................................................................................70  
15.4.  Protocol Amendment(s) ..............................................................................................[ADDRESS_1080750] (IRB) ...............................................................................71  
15.7.  Compliance with Regulatory Requirements ...............................................................71  
15.8.  Informed Consent .......................................................................................................71  
15.9.  Study File Management ..............................................................................................71  
15.10.  Study Completion .......................................................................................................71  
15.11.  Confidentiality ............................................................................................................71  
15.12.  Compensation, Insurance, and Indemnity ..................................................................72  
15.13.  Financial Disclosure ...................................................................................................72  
15.14.  Records Retention .......................................................................................................72  
15.15.  Publication Policy .......................................................................................................72  
16. REFERENCES ...........................................................................................................73  
17. APPENDIX A: MAYO TBI SEVERITY CLASSIFICATION SYSTEM ................[ADDRESS_1080751] OF TABLES 
Table 1:  Emergency Contact [CONTACT_7171] ...................................................................................4  
Table 2:  Abbreviations and Special Terms ...............................................................................18  
Table 3:  Study Objectives and Endpoints .................................................................................24  
Table 4:  Schedule of Assessments ............................................................................................[ADDRESS_1080752] OF FIGURES 
Figure 1:  Study Design ...............................................................................................................[ADDRESS_1080753]-traumatic stress disorder (PTSD). This new molecular entity is a 
modulator of the N -methyl-D-aspartate receptor (NMDAR), and acts as a co-agonist to glutamate 
at the NMDAR. The NMDARs are a large family of ionotropic glutamate receptors found 
predominantly in the central nervous system (CNS). ( Hollmann 1994, Paoletti 2007)   
Glutamate, the physiologic agonist at NMDAR, is the major excitatory neurotransmitter in the 
CNS. NMDARs are tetrameric, mixed ion channels (i.e., Ca+2, Na+, and K+) containing two 
glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits. There are a number 
of variants of the glycine binding subunits and four gene products of the glutamate subunits 
referred to as GluN2A, GluN2B, GluN2C, and GluN2D. Full activation of NMDA receptors 
requires the simultaneous binding of both co-agonists, glycine and glutamate. (Hansen 2017)  
Unlike NMDAR antagonists, which block or inhibit the NMDAR, and unlike  D-cycloserine 
(DCS, an NMDAR partial agonist), which mediates its effects through binding at the GluN1 
glycine co-agonist site, NYX-783 modulates the NMDAR by [CONTACT_4639] a unique modulatory 
site. NYX-783 binding to this novel site triggers altered receptor conformation, resulting in 
activity at all four GluN2 subtypes (GluN2A, GluN2B, GluN2C, and GluN2D). NMDAR-
mediated synaptic plasticity is thought to be a primary mechanism in the formation of new 
memories and NMDA receptor subunits have differential roles in fear acquisition and extinction.  
PTSD is a common and often severe condition that is evoked by a terrifying event, either 
personally experienced or witnessed by [CONTACT_39359]. (APA 2013) Most people exposed to 
severe traumatic events may have temporary difficulty adjusting and copi[INVESTIGATOR_007], but with time 
symptoms get better. In PTSD, symptoms such as re-experiencing traumatic event, avoidance, 
numbing and elevated arousal show no spontaneous improvement, with symptoms lasting for 
months or even decades, and interfering with daily functioning and interpersonal relationships. 
(Almli 2014) The lifetime prevalence of PTSD is about 8% in the general population, but occurs 
in much higher proportions in special populations at higher risk for exposure to trauma. 
(Kilpatrick 2013, Almli 2014) A meta-analysis of 33 studies found that the prevalence of PTSD 
in service members returning from deployment in Afghanistan and Iraq was 23%. ( Fulton 2015) 
PTSD is associated with significant psychological and physical burden on the individual level, 
and economic burdens from societal aspects. (Ellis 2018)  
PTSD, according to the DSM-5 diagnostic criteria, is characterized by 4 major symptom clusters 
following a traumatic event. The symptom categories cover: 1) intrusive symptoms:  traumatic 
event persistently re-experienced through unwanted upsetting memories, nightmares, flashbacks, 
emotional distress after exposure to traumatic reminders, physical activity after exposure to 
traumatic reminders; 2) avoidance symptoms, including trauma-related thoughts or feelings and 
trauma-related external reminders; 3) negative alterations in cognition and mood  (examples 
include inability to recall key features of the trauma, overly negative thoughts and assumptions 
about oneself or the world, exaggerated blame of self or others for causing the trauma, negative 
affect, decreased interest in activities, feeling isolated, or difficulty experiencing positive affect); 
and 4) alterations of  arousal and reactivity symptoms  incorporating irritability or aggression, 
risky or destructive behavior, hypervigilance, heightened startle reaction, difficulty 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 22  concentrating, or difficulty sleepi[INVESTIGATOR_007]. In addition, DSM-5 
al recurrently experiences depersonalization and/or 
derealization. ( APA 2013)  
Beyond the core mental symptom categories of PTSD, impairments have been identified in a 
number of domains of cognitive functioning , including working memory, executive functions, 
sustained attention, and processing speed. ( Twamley 2009, Kanagaratnam 2007, Samuelson 
2006)  
In a meta-analysis of data from 21 placebo-controlled trials, selective serotonin re-uptake 
inhibitors (SSRIs) were found to be superior to placebo in the treatment of PTSD, but the effect 
size was small (standardized mean difference = -0.23). ( Hoskins 2015) Currently, two SSRIs, 
sertraline and paroxetine, have been approved by [CONTACT_785683]. Fluoxetine and 
venlafaxine also have shown efficacy in reducing PTSD symptoms in placebo -controlled 
clinical trials. ( Hoskins 2015) Overall, however, response rates with SSRIs have rarely exceeded 
60%, and less than 20-30% of subjects have been shown to achieve full remission. (Berger 2009) 
The premise of this trial stems from the role of NMDARs in a number of physiological and 
pathological processes, including PTSD ( Steckler 2012, Sherin 2011, Ravindran 2009) and 
affected cognitive domains. ( Gonzalez 2015, Tsai 2016 ) The key element of PTSD is a pervasive 
sense of impending danger, fearfulness, and heightened arousal in situations where no actual 
threat or danger is present. ( Pole 2007) Persistent fear memory may be the result of enhanced 
fear acquisition, impaired fear extinction, and/or deficiencies in contextual processing. 
(Garfinkel 2014)   
NMDARs have been shown to regulate fear acquisition and extinction due to their role in 
synaptic development and plasticity. ( Radulovic 2018, Luchkina 2018 ) Further, there appears to 
be differential roles for the NMDAR receptor subtypes. For example, GluN2A receptor subunit 
activation may have a role in the formation and/or stabilization of new learned fear responses, 
whereas GluN2B receptor activation may be involved with the suppression/extinction of learned 
fear responses. ( Dalton 2012)  
NYX-783 has exhibited efficacy in several pre-clinical models of PTSD symptoms. Specifically, 
in a model of intrusive fear memory, a single oral dose of NYX-783 (1 mg/kg) facilitated 
extinction of conditioned fear similarly to a single dose of the positive control DCS (15 mg/kg 
given subcutaneously). When contextual fear memory was measured 14 days after the original 
conditioning session, spontaneous recovery of freezing behavior was observed in rats previously 
treated with DCS. Importantly, no spontaneous recovery of freezing behavior was observed in 
rats previously treated with NXY-783. Thus, a single treatment with NYX-783 reduced freezing 
in a rat model of intrusive fear memory when measured either proximal or remote to fear 
conditioning. Additionally, in an assay that measures affective state (heterospecific rough-and-
tumble play), NYX-[ADDRESS_1080754] dose range. NYX-783 also decreased rat immobility in the Porsolt forced swim assay, 
which exhibits high predictive validity for antidepressant activity. These data may be significant 
given the widespread use of antidepressants to treat PTSD symptoms. 
Safety pharmacology studies indicate that NYX-783 has low potential for off-target 
pharmacology. NYX-783 had no significant activity in a panel of 80 receptor-binding assays that 
included gamma-aminobutyric acid (GABA), opi[INVESTIGATOR_2573], serotonin, and tachykinin receptors, ion 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 23  channels, and transporters. NYX-783 was inactive in modulating human ether-à-go-go-related 
gene (hERG) activity and had no effect on hemodynamic or ECG parameters in male isolated 
guinea pig hearts (Langendorff method) up to µM.  
In general, NYX-783 was well-tolerated after single oral doses up to and including 600 mg/kg in 
rats and 1000 mg/kg in dogs. In a 91-day repeat-dose study, NYX-[ADDRESS_1080755]-level (NOAEL) in rats was the highest dose 
tested, 500 mg/kg. In the daily repeat-dose, 91-day dog toxicology study, NYX-783 was 
evaluated at doses of 2, 6, and 20 mg/kg. There were notable changes in liver parameters at 6 and 
20 mg/kg; the liver-associated findings at 6 mg/kg were considered non-adverse and recovered 
after a 4-week drug holiday. Also, at the 20 mg/kg dose, elevations in serum levels of liver 
enzymes, primarily ALT, were observed. The liver-associated findings at 20 mg/kg were 
considered adverse and did not recover. Therefore, the NOAEL in dog was 6 mg/kg/day. All 
adverse observations occurred at doses in excess of the planned clinical doses.   
 Results are available from all [ADDRESS_1080756]-in-human study of NYX-783 
(NYX-783-1002) in which healthy male and female subjects were enrolled. In this study, safety 
and pharmacokinetics of single doses (10, 50, 200, and 600 mg) and multiple doses (once daily 
for 7 days of 2, 50, and 200 mg) of NYX-783 were evaluated. Seventy subjects were included in 
the safety population and 54 active-treated subjects were included in the PK population. NYX-
783 was safe and well-tolerated at the studied doses. No grade 3, grade 4, or serious adverse 
events were reported. Further, there were no laboratory results or ECG findings reported as 
adverse events. There were 2 unrelated adverse events (emesis and viral gastroenteritis) that lead 
to withdrawal from the study. There were 2 mild adverse events (headache and fatigue) that the 
investigator considered possibly related to NYX-783. A maximum tolerated dose was not 
reached in the study. 
The PK data from study NYX-783-[ADDRESS_1080757] dose. 
Concentrations declined in a roughly monophasic manner over 24 hours, and a roughly biphasic 
manner over 48 hours after 7 days of dosing. NYX-783 had a t 1/2 of approximately 4 hours and 
demonstrated dose-proportional PK with minimal accumulation following QD dosing for 7 days. 
Data suggests that NYX-783 can be administered with or without food, and, plasma exposures to 
NYX-783 in the elderly cohort were comparable. The majority (50-60%) of the administered 
dose of NYX-783 was excreted unchanged in the urine. CSF samples were obtained in subjects 
taking a single 50 mg dose of NYX-783. NYX-783 crossed the blood brain barrier, with CSF 
concentrations at 4 and 8 hours approximately 12% to 14% of plasma C max at the same dose 
level.  
 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 26  6.1.3. Exploratory Criteria  
 
 
 
 
   

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 27  7. INVESTIGATIONAL PLAN 
7.1. Overall Study Design and Plan: Description 
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 
outpatient study of approximately 12 weeks duration (Screening: 3 weeks; Treatment: 8 weeks; 
Follow-up: 1 week). In this study, a sequential parallel comparison design (SPCD) will be used 
to examine the efficacy and safety of oral NYX-783 compared to placebo in the treatment of 
PTSD symptoms. On Day 1, approximately 156 eligible subjects will be randomized to receive 
placebo, NYX-783 50 mg QD, or NYX-783 10 mg QD in a 4:1:1 ratio, respectively (Figure 1). 
Placebo non-responders (CAPS-5 total score reduction from baseline [Day 1] 35% and CAPS-5 
total score  at Week 4) and placebo responders identified during Stage 1 (Week 1-4) will then 
be then re-randomized in a blinded fashion to placebo, NYX-783 50 mg QD or NYX-783 10 mg 
QD in Stage 2 (Weeks 4-8) in a 3:2:[ADDRESS_1080758] received either 4 weeks of NYX-783 50 mg QD or 10 mg QD (and 4 weeks of placebo) or 
8 weeks of placebo. The sample size estimate is based on an assumption of 15% dropout during 
period 1, and 11 % dropout rate in period 2. 
All potential study participants must provide written informed consent before initiating any 
protocol-specified procedures. A 2-step approach will be used to identify the study population 
during the Screening period:   
1) Screening visit (Days -28 to -14) . Potential subjects will be screened for the presence of 
PTSD using the self-report PCL-5, with the Life Events Checklist for DSM-5 (LEC-5) being 
used to assess the nature of the primary traumatic event. Subjects with a PCL-5 severity score 38 will be interviewed by [CONTACT_785684]-5 (SCID-5-CT) to exclude comorbidities. The CAPS-[ADDRESS_1080759] month will be assessed based on the CAPS-5; a 
CAPS-5 total  Other screening procedures will include 
demographics, medical history, vital sign measurements, PE, height, weight, ECG, laboratory 
samples (chemistry, hematology, urinalysis, drug screen), suicidality, and concomitant 
medication information. Other clinical measures will be used to assess sleep quality, cognitive 
effects, and mood and anxiety symptoms.  
2) SAFER interview (Day -14 ± 3 days ). Subjects who meet the diagnostic criteria at the 
Screening visit will then participate in telephone-based interview ( SAFER interview ) to confirm 
the diagnosis of PTSD and review potential comorbidities and study exclusion criteria. Those 
subjects meeting the diagnostic and selection criteria will be eligible for proceeding to the 
randomization visit. 
On Day 1, eligible subjects will be randomized to receive NYX-783 50 mg QD, NYX-783 10 mg 
QD, or matching placebo. Assessments on Day 1 will include vital signs, ECG, weight, 
laboratory samples (pharmacogenomics [optional], plasma concentration, RNA (optional), 
chemistry, hematology, urinalysis and drug screen), suicidality, and concomitant medication 
review. Clinical measures will be used to assess severity of PTSD symptoms, sleep quality, 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 28  cognitive effects, and mood and anxiety symptoms. Study drug will be administered at the 
investigative site on Day 1 and dispensed for subsequent outpatient administration. 
At the follow-up visits on Weeks 2, 4, 6, and 8/early termination, PTSD severity in the past week 
will be assessed by [CONTACT_785685]-[ADDRESS_1080760] dose of study drug. 
Blood samples for evaluating plasma concentrations will be collected at Week 4 and Week 
8/early termination. Blood samples for pharmacogenomic (PGX) testing will be collected on Day 
[ADDRESS_1080761] signed consent to participate in this exploratory analysis. Optional 
blood samples for biomarker (RNA) testing will be collected on Day 1, Week 4, and Week 
8/early termination.  
Safety throughout the entire study will be assessed by [CONTACT_20721], vital sign measurements, 
weight, PE, ECG testing, clinical laboratory testing, and the Sheehan Suicidality Tracking Scale 
(S-STS) instrument.  
Rater qualification, training, and surveillance will be centrally monitored during the study. 
A Data and Safety Monitoring Board (DSMB) will perform periodic reviews of available safety 
data to ensure it is safe to proceed. 
 
 
 
  
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020
 
Aptinyx Confidential 32l) Stage 2 dosing begins on the day after the Week 4 visit. 
m) Includes concurrent medical and psychiatric history. 
n)  
o) Use interactive response technology for study drug dispensing. 
p) [ADDRESS_1080762]-therapy. 
q) Clinical labs should be fasted except for screening. 
r) Only if required for adverse event follow-up. 
s) Rating based on the past month 
t) Rating based on the past week 
u) Use since last visit  version after screening. 
v) Women of childbearing potential. 
w) Remote visit (optional.  Only if necessary, due to COVID-19 health emergency) 
x) Visit window is ± 7 days. 
 
 
 
 
 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 33  7.2. Scientific Rationale for Study Design 
This Phase 2, proof-of-concept, placebo-controlled study uses a sequential parallel comparison 
design (SPCD), which is appropriate due to the short active treatment phases (two 4-week 
double-blind treatment periods) and the expected relatively meaningful placebo response rate. 
The purpose of conducting this exploratory study is to investigate the safety and tolerability of 
NYX-783 in a PTSD population, and to characterize the response profile of NYX-783 for the 
treatment of PTSD symptoms evaluated by [CONTACT_426134], avoidance, negative alterations in 
cognition and mood, and arousal & reactivity subscores as well as CAPS-5 total score. The 
results from this study will be utilized to inform the future NYX-783 development plans.   
The SPCD is an adaptive design that allows for re-randomization of placebo subjects (both 
"non-responders" initial stage of the study to placebo or active 
treatment in a subsequent stage of the trial. In this study, d - population 
of Stage 1 arms [1 = placebo], [2 = NYX-783 50 mg QD], [3 = NYX 783 10 mg QD] and the 
 non- in Stage 2 arms [7 = placebo], [8 = NYX-783 50 
mg QD], [9 = NYX 783 10 mg QD] are pooled to yield a single p-value for treatment 
comparison. Estimation of the treatment effect is enhanced by [CONTACT_785686] (Tamura 2011), and the SPCD design is appropriate for earlier stage trials, such as 
moderately-sized Phase 2 studies. ( Tamura 2011, Baer 2013 ) The SPCD design aims to increase 
the probability of demonstrating a treatment effect, especially if the Stage 1 placebo response 
rate is high. (Chen 2011) The design reduces the impact of placebo response and thus improves 
the power of the study, which in turn allows for an adequately powered proof-of-concept trial 
with a smaller sample size and mitigation of the untoward effect of a placebo response. (Baer 
2013) All efficacy analyses will be evaluated at the 0.10, one- -sided is 
appropriate because the primary objective of the study is to demonstrate that NYX-[ADDRESS_1080763] of NYX-783 treatment after re-
randomization of subjects initially allocated to one of the active treatment arms [2] and [3] to 
placebo arms [10] and [11]. The re-randomization of both placebo-responders and placebo 
non--responders from Stage 1 will characterize the response profile of subjects with initial high 
vs. low placebo response rate in Stage 2 drug treatment arms [5], [6] vs. [8], [9] respectively.  
Altered gene expression associated with PTSD has been characterized in peripheral blood 
samples collected from civilian and military populations in clinical trials. ( Banerjee 2017 ) 
Analysis of RNA, including microRNA (miRNA) and/or messenger RNA (mRNA), provides a 
new opportunity to understand the biological pathways underlying PTSD, with the potential to 
establish biomarker-driven subgroups within the PTSD diagnosis, and/or to serve as a platform 
for pre-clinical mechanistic studies ( Glatt 2013).  
7.2.1. Subject Population Rationale 
The goal of the study is to recruit subjects with a clearly identifiable primary traumatic event 
during adulthood.  
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 34  Inclusion criterion #2 clarifies that subjects with delayed-onset PTSD (i.e., the full diagnostic 
criteria for PTSD are not met until at least 6 months after the event, although the onset and 
expression of some symptoms may be immediate) ( APA 2013) will be allowed to enter into the 
study if the full diagnostic criteria for PTSD according to the DSM-[ADDRESS_1080764] 6 months 
prior to screening.  
In delayed-onset PTSD, which occurs in about 25% of PTSD cases, ( Utzon-Frank 2014) subjects 
might have experienced subthreshold PTSD symptoms after the trauma. Potentially, some 
additional trauma then impairs the index traumatic event. 
Consequently, subthreshold PTSD symptoms become more severe and evolve into clinically 
manifest PTSD. For inclusion into the study, at least [ADDRESS_1080765] 
be present prior to screening (inclusion criterion #2), with no further traumas in that same 6-
month period (exclusion criterion #4).  
Subjects meeting inclusion criteria #2, #3 and #4 enrich the study with a moderate-to-severe 
PTSD population. A score of 38 or higher on PCL-5 indicates likely PTSD in both civilian and 
veteran populations. ( Blevins 2015, Hoge 2014 ) The timeframe associated with the primary 
traumatic event as defined by [CONTACT_461630] #2 is designed to minimize spontaneous 
remission during the study, while exclusion criteria #1, #3, and #4 control for significant 
chronicity of the disease and minimize Axis-II disorders overlappi[INVESTIGATOR_785664]. Exclusion criterion #[ADDRESS_1080766] when exposed to trauma, and certain phenotype (i.e., if affect dysregulation and 
interpersonal dysfunction are primary over other core PTSD symptoms).  
Exclusion criteria #6, #7, #9, #14, and #16 minimize disease comorbidities, and #5 minimizes 
TBI consequences associated with the primary traumatic event. The purpose of exclusion criteria 
#10, #11, #12, and #13 is to exclude subjects taking psychoactive drugs due to either their 
potential influence on PTSD symptoms (different classes of antidepressants, sleep inducers with 
long half-life) or potential interference with NYX-[ADDRESS_1080767] of NMDA 
modulation on sleep architecture, interference with  the  pharmacology of NYX-783 (i.e., there is 
a possible interaction between gabapentinoids [pregabalin, gabapentin], interaction with and 
certain NMDA receptor complexes). ( Chen 2018 )  
7.3. Justification of Dose 
The planned dose levels in this study are NYX-783 50 mg/day and 10 mg/day. Based on the 
preliminary PK results of the Phase 1, first-in-human study in healthy male and female 
volunteers (NYX-783-1002), the maximum plasma concentration (C max) of NYX-783 50 mg is 
expected to be approximately 0.8 g/mL. Total exposure (area under the plasma-concentration 
curve [AUC 0-24]) is expected to be approximately 5.[ADDRESS_1080768], NYX-783, when administered to rats as a single oral 
dose of 1 mg/kg, facilitated fear extinction learning on extinction Days 1-4 and prevented the 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 35  re-consolidation of fear memory when retested on Day 14 compared to vehicle. At this 
pharmacologically-active dose (1 mg/kg) in rats, the plasma C max  
In addition, a single dose of NYX-[ADDRESS_1080769], preventing freezing behavior after one dose of drug in rodents and preventing recovery of 
fear after 14 days. One objective of this Phase 2 study is to confirm that the observed preclinical 
long -lasting effects are translatable to humans, i.e., once daily (QD) administration provides 
long-lasting benefits. 
The pharmacologic effects of NYX-783 are currently believed to be driven primarily by C max.  
Thus, the dose planned for the current clinical study is expected to result in human plasma 
concentrations that are within the C max range that was associated with positive effects on -fear 
extinction measures. 
The 50 mg dose is 1/12th of the maximum single dose (600 mg) and 25% of the maximum 
multiple dose (200 mg) given once daily for 7 days in the Phase 1 trial (NYX-783-1002), which 
were safe and well-tolerated. The 600 mg single dose as well as the 200 mg multiple dose were 
associated with PK exposures (C max and AUC) below the NOAEL for both the dog and rat in the 
Good Laboratory Practice toxicology studies. In the Phase 1 trial, NYX-783 had a terminal 
elimination half-life (t ½) of approximately 4 hours and demonstrated no accumulation with once 
daily dosing over 7 days. In all single-dose groups, approximately 57% of the administered dose 
was recovered as NYX-[ADDRESS_1080770] meet all of the following 
criteria: 
1. Male and female subjects between the ages of 18 to 65 years (inclusive) at the time of 
signing the informed consent. 
2. A primary diagnosis of PTSD (DSM-5 criteria, APA 2013) according to the CAPS-[ADDRESS_1080771], with the primary traumatic event occurring 12 months prior to screening. 
NOTE: In cases delayed--onset must be 
present for at least [ADDRESS_1080772] at 
screening and be practicing an adequate method of birth control (e.g., oral or parenteral 
contraceptives, intrauterine device, barrier, abstinence). Subjects may not be breastfeeding or 
plan to become pregnant or donate ova during the study and for [ADDRESS_1080773] dose of 
study drug. 
7. Male subjects who are sexually active with female partner(s) must agree to the following 
during the study and for [ADDRESS_1080774] dose of study drug: a) use an acceptable 
method of birth control (condom with spermicide or surgical sterilization) and b) refrain from 
sexual activity with female partners who do not use an acceptable method of birth control. 
Barrier contraception (condom with spermicide) must  be used by [CONTACT_785687] [ADDRESS_1080775] Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from participation in this 
study: 
1. Complex PTSD, defined as a condition that may develop following exposure to an event 
or series of events of an extreme and prolonged or repetitive nature of which the subject 
experienced as extremely threatening or  horrific and from which escape was difficult or 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 37  impossible (e.g., torture, slavery, genocide campaigns, prolonged domestic violence, 
repeated childhood sexual or physical abuse). If affect dysregulation and interpersonal 
dysfunction that are primary over other core PTSD symptoms, 
opi[INVESTIGATOR_1649], they should be considered as exclusionary criteria. NOTE: Non-interpersonal 
trauma (e.g. motor vehicle accident, mass transportation accident, domestic fire, mass 
shooting survivor) prior to 18 years of age are not exclusionary, and, the trauma can be 
considered the primary traumatic event (index trauma). 
2. Trauma focused psychotherapi[INVESTIGATOR_44793], prolonged exposure therapy, cognitive 
behavioral therapy, eye movement desensitization and reprocessing therapy (EMDR) 
within 30 days prior to screening or during the study. 
3. Primary traumatic event occurred prior to 2001. 
4. Primary traumatic event was followed by [CONTACT_785688][INVESTIGATOR_169572] 6 
months prior to screening. 
5. Primary traumatic event was associated with traumatic brain injury (TBI) categorized as 
Moderate-to Severe TBI, according to the Mayo TBI Severity Classification System. 
(Malec 2007) (See Appendix A) 
6. Substance use disorder within the 6 months prior to screening. Use of any illicit drugs of 
abuse during the study period is prohibited.  
7. History of alcohol abuse within the 6 months prior to screening. NOTE: Up to an average 
of 1 drink/day is allowed during the study.  
8. Positive screen for alcohol or drugs of abuse, including phencyclidine, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_858], methadone, cocaine, cannabinoids, and amphetamines at 
screening or Day 1. Subjects who have a positive screen for cannabinoids or other 
medically prescribed drugs of abuse at screening, must have a negative screen at Day 1 
and agree not to use during the study. 
9. Any history of schizophrenia or other psychotic disorder, bipolar disorder, psychosis, or 
other Axis 1 disorder (except for major depressive disorder or anxiety disorders that 
followed exposure to the trauma or an anxiety disorder that showed a worsening after 
trauma). Anxiety disorders (such as selective mutism, specific phobia, social anxiety 
disorder, panic disorder, agoraphobia, and generalized anxiety disorder) are exclusionary 
only if the diagnosis preceded the primary traumatic event, and, the subject was seeking 
and received treatment for the symptoms prior to the primary traumatic event. NOTE: A 
current secondary diagnosis of major depressive disorder without full remission is not 
exclusionary; if treated, the dose of a permitted antidepressant must be stable for at least 
30 days prior to screening and expected to continue during the study. 
10. Clozapi[INVESTIGATOR_785665] 12 months prior to screening or 
during the study.  11. Current use of medications with primarily CNS activity (e.g., antipsychotics, 
anticonvulsant drugs [including gabapentinoids], psychostimulants, 
benzodiazepi[INVESTIGATOR_1651], methylphenidate, doxazosin, prazosin, clonidine, first-
generation sedating H1 antihistamines, quetiapi[INVESTIGATOR_050], eszopi[INVESTIGATOR_11123], zolpi[INVESTIGATOR_638283]-release, or any other sedative-hypnotic medications) within 3 days prior 
to screening or during the study. NOTE: Use of certain non-benzodiazepi[INVESTIGATOR_785666]-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 38  inducers (e.g., zolpi[INVESTIGATOR_620761]-release [up to 10 mg at bedtime], zaleplon 
[up to 20 mg at bedtime]), melatonin, or ramelteon for sleep are allowed.  
12. Use of nefazodone, selective serotonin reuptake inhibitors (SSRIs, such as 
fluoxetine, sertraline, escitalopram, citalopram, paroxetine), serotonin and 
norepi[INVESTIGATOR_5608] (SNRIs, such as desvenlafaxine, duloxetine, 
venlafaxine), reversible and non-reversible  monoamine oxidase inhibitors (such 
as selegiline, phenelzine, tranylcypromine), tricyclic antidepressants (such as 
amitriptyline, imipramine, nortriptyline), noradrenergic and specific serotonergic 
antidepressant (NaSSA) mirtazapi[INVESTIGATOR_050], serotonin modulator and stimulator 
antidepressants (such as vilazodone or vortioxetine), or the norepi[INVESTIGATOR_238], 
serotonin and dopamine reuptake inhibitor bupropi[INVESTIGATOR_696827] 30 days (90 days for 
fluoxetine) prior to screening or during the study. NOTE : Subjects on stable 3
therapy during the study with no expected change in dose. 
13. Treatment with an injectable depot neuroleptic within 90 days prior to screening 
or during the study.  
14. Subjects who meet the criteria for suicidal intent, plan and/or behavior on the S-STS at 
screening or Day 1. These criteria are a score of 3 or 4 on questions 2 or 13, or 2 or 
higher on any of the following questions: 1a (only if 1b is coded YES), 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, or 14. 
15. In the process of litigating for compensation for a psychiatric disorder. Subjects who are 
in the process of applying for medical or VA benefits and/or those who have settled a 
disability claim prior to enrollment in the trial are eligible.  
16. seizures (history of childhood febrile seizures are not exclusionary), epi[INVESTIGATOR_002], or stroke. 
17. History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor (NMDAR) 
ligands, including ketamine, dextromethorphan, memantine, methadone, 
dextropropoxyphene, or ketobemidone, as well as current use of such agents. 
18. Received an investigational drug product or device within 30 days (or [ADDRESS_1080776]) of dosing. 
19. Previously received NYX-783. 
20. (males) or 470 (females) milliseconds (msec) or an ECG that is not suitable for QT 
measurements (e.g., poorly defined termination of T-  
21. A known familial history or known presence of long QT syndrome, or a known history of 
past or current clinically significant arrhythmias or ischemic heart disease. 
22. Body mass index >35 kg/m2 at screening. 
23.  at screening. 
24. Uncontrolled Type I or Type II diabetes mellitus or uncontrolled hypertension. 
25. Estimated creatinine clearance <60 mL/minute calculated by [CONTACT_16424]-Gault 
equation at screening or history of renal disease, as assessed by [CONTACT_785689]-designated medical monitor. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 39  26. Known diagnosis of a current infectious disease, including human immunodeficiency 
virus infection, hepatitis, or other ongoing infectious disease that the investigator 
considers clinically significant.   
27. Current evidence of dysplasia or history of malignancy (including lymphoma and 
leukemia) in the last 5 years, with the exception of successfully treated non-metastatic 
basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the 
cervix. 
28. History of gastrointestinal disease or surgery (except simple appendectomy or hernia 
repair), leading to impaired drug absorption. 
29. Known abnormal laboratory results, ECG results, medical history or concurrent 
conditions which, in the opi[INVESTIGATOR_26335], would preclude safe study 
participation or interfere with study procedures/assessments. 
30. Uncorrected hypothyroidism or hyperthyroidism. NOTE: subjects with compensated 
hypothyroidism, with normal thyroid-stimulating hormone levels may be enrolled. 
31. Impaired hepatic function characterized by a previous known diagnosis of chronic liver 
disease and/or the presence of direct bilirubin >1.5x, or, alanine transaminase, aspartate 
transaminase, alkaline phosphatase, or gamma-glutamyl transferase >2x the upper limit 
of normal at screening. 
32. Current borderline personality disorder, antisocial personality disorder, or other 
personality disorder (e.g. subject showed pervasive pattern of disregard for and violation  
of the rights of others, or subject has had previous repetitive suicidal behavior [including 
aborted, interrupted or ineffective suicide attempts, gestures], self-mutilating behavior, or with study participation. 
33. Use of NMDAR-binding drugs (e.g., ketamine, dextromethorphan, memantine, 
methadone, lamotrigine, esketamine) within 60 days prior to dosing or during the study. 
34. 3,4-Methylenemetamphetamine (MDMA)-assisted psychotherapy within 90 days prior to 
screening or during the study. 
35. Expected to initiate any psychotherapy during the study. 8.3. Screen Failures 
Subjects who sign and date the ICF but who fail to meet the inclusion and exclusion criteria are 
considered screen failures. Reason(s) for screen failure must be documented by [CONTACT_785690] a timely fashion. Subjects may be rescreened if the investigator 
considers rescreening appropriate. If a screened subject is not eligible for randomization, the 
primary reason for failure should be recorded on the applicable eCRF. The primary reason for 
screen failure should be recorded according to one of the following categories: did not meet 
inclusion criteria; did meet exclusion criteria; protocol violation or subject noncompliance 
(specify); lost to follow-up; withdrew consent; other (specify). 
8.4. Subject Withdrawal Criteria 
A subject may withdraw consent at any point during the study. The investigator may discontinue 
a subject at any time if it is deemed medically appropriate, or for subject noncompliance with 
Clinical Protocol NYX-783-[ADDRESS_1080777] to 
follow-up (i.e., those subjects whose status is unclear because of failure to appear for study visits 
without stating an intention to withdraw), the investigator should document in the source 
documents steps taken to contact [CONTACT_423]. Subjects are to be withdrawn from the study if any 
of the following criteria are met: 
 Occurrence of an AE, intercurrent illness, or laboratory abnormality which, in the opi[INVESTIGATOR_785667]. 
 Withdrawal of informed consent 
 Noncompliance with protocol procedures 
 Lost to follow-up 
 Pregnancy 
 Study termination by [CONTACT_785691]:  COVID-[ADDRESS_1080778] dose of study drug. 
 Oral or parenteral contraceptives 
 Intrauterine device (either hormonal or non-hormonal type acceptable) 
 Barrier (condom, contraceptive sponge, diaphragm, or cervical cap with spermicide) 
 Abstinence 
Females not of childbearing potential are defined as those who have been surgically sterilized 
(hysterectomy, bilateral oophorectomy, or tubal ligation) or who are post-menopausal 
(amenorrhea) for at least [ADDRESS_1080779] agree to use barrier contraceptives (condom with 
spermicide) during the study and for [ADDRESS_1080780] dose of 
study drug. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 41  9. SCHEDULE OF PROCEDURES 
9.1. Screening Period (Day -28 to -14) 
 Informed consent form (ICF) must be signed before any protocol-directed procedures are 
performed. A separate ICF for optional pharmacogenomics (PGX) and PAX blood sampling 
will also be administered at the screening visit. 
 Inclusion/exclusion criteria 
 Demographics and habits (alcohol and/or illicit drug use, employment history, smoking 
history, and index traumatic event) 
 Medical and psychiatric history (including non-pharmacologic interventions) 
 PTSD diagnosis, according to DSM-5 (SCID-5-CT to exclude co-morbidities and CAPS-5 to 
diagnose PTSD)  
 LEC-5 (part of PCL-5 with LEC-5 and Criterion A) 
 S-STS (last month version) 
 Vital sign measurements (after at least [ADDRESS_1080781], sitting or supi[INVESTIGATOR_050]) 
 Height (calculate BMI) 
 Body weight (calculate BMI) 
 PE  
 ECG (after at least [ADDRESS_1080782]) 
 Laboratory tests: 
o Clinical chemistry (calculate estimated creatinine clearance) 
o Hematology 
o HIV, hepatitis B surface antigen, hepatitis C antibody 
o Serum pregnancy test for women of childbearing potential 
o Drug and alcohol screen (serum) 
o Urinalysis 
 Clinical measures: 
o CAPS-5  
o PCL-5 (last month version) 
o HADS 
o CGI-S 
o PSQI 
o PSQI-A 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 42  o  
 Prior and concomitant medications 
 SAEs (collection begins after ICF signed) 
9.2. Day -14 (±3 days) 
Subjects who meet eligibility criteria according to the PCL-5 ( 38), SCID-5-CT, and CAPS-5 
(total score ) at screening will complete a SAFER remote phone interview. Those subjects 
confirmed to have met the study diagnostic and selection criteria as determined during the 
SAFER interview are then eligible to proceed in the study.  
9.3. Stage 1: Day 1  
 Medical and psychiatric history updates (if applicable) 
 Inclusion/exclusion criteria 
 S-STS (since last visit version) 
 Vital signs (after at least [ADDRESS_1080783], sitting or supi[INVESTIGATOR_050]) 
 Body weight 
 ECG (after at least [ADDRESS_1080784]) 
 Concomitant medications 
 Laboratory tests 
o Clinical chemistry (fasted) 
o Hematology 
o  
  
o Pregnancy test (urine) for women of childbearing potential 
o Drug (urine) and alcohol screen (breathalyzer) 
o Urinalysis 
 Clinical measures (all measures except for CAPS-[ADDRESS_1080785] measurement is 
within 14 days prior to Day 1)  
o CAPS-5 
o PCL-5 
o HADS 
o CGI-S 
o PSQI 
o PSQI-A 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 43  o  
o DES-II 
o BAC-Symbol Coding 
 Randomization  
 Study drug dispensing, dose administration (in clinic and after completion of above-noted 
study procedures), and compliance monitoring 
o Medication adherence and reminder system training 
 AEs (serious and non-serious) 
9.4. Week 2, Day 14 (±7 days) 
 S-STS (since last visit version) 
 Vital sign measurements ( after at least [ADDRESS_1080786], sitting or supi[INVESTIGATOR_050])  
 Body weight 
 Laboratory tests: clinical chemistry (fasted) 
 Clinical outcome measures 
o CAPS-5 
o PCL-5 
o HADS 
o PSQI 
o PSQI-A 
o CGI-S 
 Study drug accountability, compliance review, and dispensing 
o Medication adherence and reminder system review 
 Concomitant medications 
 AEs (serious and non-serious) 
9.5. Stage 2: Week 4, Day 28 (±3 days) 
Study drug (including extra kit) dispensed in Stage 1 may not be re-dispensed and/or 
administered in Stage 2. 
 S-STS (since last visit version) 
 Vital signs (after at least [ADDRESS_1080787], sitting or supi[INVESTIGATOR_050]) 
 Body weight 
 PE  
 ECG (after at least [ADDRESS_1080788]) 
 Laboratory tests 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 44  o Clinical chemistry (fasted) 
o Hematology 
o Plasma concentration blood sample 
o RNA (miRNA, mRNA) PAXgene® blood sample (optional) 
o Pregnancy test (urine) for women of childbearing potential 
o Drug (urine) and alcohol screen (breathalyzer) 
o Urinalysis 
 Clinical measures 
o CAPS-5 
o PCL-5 
o HADS 
o CGI-S 
o PSQI 
o PSQI-A 
o BAC-Symbol Coding 
o  
o DES-II 
 Randomization (for Stage 2) 
 Study drug accountability, compliance review, and dispensing (for next day dosing) 
o Medication adherence and reminder system review 
 Concomitant medications 
 AEs (serious and non-serious) 
9.6. Week 6, Day 42 (±7 days)  
 S-STS (since last visit version) 
 Vital signs (after at least [ADDRESS_1080789], sitting or supi[INVESTIGATOR_050]) 
 Body weight 
 Laboratory tests: clinical chemistry (fasted) 
 Clinical outcome measures 
o CAPS-5 
o PCL-5 
o HADS 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 45  o PSQI 
o PSQI-A 
o CGI-S 
 Study drug accountability, compliance review, and dispensing  
o Medication adherence and reminder system review 
 Concomitant medications 
 AEs (serious and non-serious) 
9.7. Week 8, Day 56 (±3 days) 
 S-STS (since last visit version) 
 Vital signs (after at least [ADDRESS_1080790], sitting or supi[INVESTIGATOR_050]) 
 Body weight 
 PE 
 ECG (after at least [ADDRESS_1080791]) 
 Laboratory tests 
o Clinical chemistry (fasted) 
o Hematology 
o Plasma concentration blood sample 
o  
o Drug and alcohol screen (serum) 
o Pregnancy test (urine) for women of childbearing potential 
o Urinalysis 
 Clinical outcome measures 
o CAPS-5 
o PCL-5 
o HADS 
o CGI-S 
o PSQI 
o PSQI-A 
o BAC-Symbol Coding 
o  
o DES-II 
o  

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 46   Study drug accountability and compliance review 
o Medication adherence system review and retrieval of device (if applicable)  
 Concomitant medications 
 AEs (serious and non-serious) 
9.8. Early Termination Visit 
 S-STS (since last visit version) 
 Vital signs (after at least [ADDRESS_1080792], sitting or supi[INVESTIGATOR_050]) 
 Body weight 
 PE 
 ECG (after at least [ADDRESS_1080793]) 
 Laboratory tests 
o Clinical chemistry (fasted) 
o Hematology 
o Plasma concentration blood sample 
o  
o Drug and alcohol screen (serum) 
o Pregnancy test (urine) for women of childbearing potential 
o Urinalysis 
 Clinical measures 
o CAPS-5 
o PCL-5 
o HADS 
o CGI-S 
o PSQI 
o PSQI-A 
o BAC-Symbol Coding 
o  
o DES-II 
o  
 Study drug accountability and compliance review 
o Medication adherence system review and device retrieval (if applicable) 
 Concomitant medications 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 47   AEs (serious and non-serious) 
9.9. Safety Follow-up Visit ([ADDRESS_1080794]-therapy ±3 days) 
The following safety assessments are to be performed only if required for AE follow-up: 
 Vital signs (after at least [ADDRESS_1080795], sitting or supi[INVESTIGATOR_050])  
 Body weight 
 PE 
 ECG (after at least [ADDRESS_1080796]) 
 Laboratory tests 
o Clinical chemistry (fasted) 
o Hematology 
o Urinalysis 
The following assessments are to be performed for all subjects at this visit: 
 Concomitant medications 
 AEs (serious and non-serious) 
 
 
9.[ADDRESS_1080797] cannot be physically present at the investigational site (due to the 
COVID-19 health emergency) within the time window of their scheduled visits, the following 
assessments will be completed remotely through videoconference or phone call with site staff: 
 Reporting of AEs 
 concomitant medication 
 the evaluation of suicidality (SSTS), and the  
 administration of the CAPS-5 
Remote assessments can only be done for Week 2, Week 6, and Safety Follow-up visits. The 
mode of assessment will be captured in the clinical database. Baseline, Week 4 (re-
randomization) and Final Visit Week 8/ET must be completed at the site. The rest of the safety 
procedures such as blood and urine sampling, vital signs, ECG and physical exam must be done 
within [ADDRESS_1080798], at each subsequent study visit for accountability.  
10.2. Randomization and Blinding 
The study will be conducted as a placebo-controlled, double-blind study. The randomization 
schedule will be produced by [CONTACT_785692].  
On Day 1, subjects will be randomized to receive placebo, NYX-783 50 mg QD, or NYX-783 10 
mg QD in a 4:1:1 ratio, respectively. Placebo responders and placebo non-responders (CAPS-5 
total score reduction from baseline 35% and total CAPS-5 total 
identified at the completion of Stage 1 (Weeks 1-4) in a blinded fashion; then, each group (i.e., 
placebo responders and placebo non-responders) will be re-randomized in a blinded fashion to 
placebo, NYX-783 50 mg QD, NYX-783 10 mg QD in a 3:2:2 ratio, respectively, for Stage 2 
(Weeks 4-8) treatment. Subjects who received active treatment during Stage 1 will receive 
placebo in Stage 2.  
The authorized investigative site personnel will obtain blinded kit assignments using an 
interactive response technology (IRT) system. The blinded dose information may only be 
obtained by [CONTACT_093] (or designee) in an emergency, where the information may have an 
impact on further treatment decisions or aid in the emergency treatment of the subject. Every 
effort must be made to contact [CONTACT_1152]. 

Clinical Protocol NYX-783-[ADDRESS_1080799] compliance. A 
smartphone--based video recording technology platform will be utilized for monitoring 
compliance with study drug administration. The platform uses artificial intelligence on 
smartphones to confirm medication ingestion. Additionally, built-in reminders and a 
communication system may allow for real-time intervention in case of study drug interruptions. 
Use of the platform will be required for all subjects. The platform will be provided to subjects 
preloaded onto a smartphone, or subjects will download the platform onto his/her personal 
mobile device during a study visit. Video recordings will be encrypted and transmitted to a 
secure centralized location for further analyses, including testing for duplicate enrollment at 
other investigative sites. The captured data and video will be reviewable through a roles and 
restricted system ensuring privacy of information. The system is compliant with the Health 
Insurance Portability and Accountability Act (HIPAA), which protects the privacy and security 
of healthcare information. Phone numbers of the subjects may also be collected and stored in an 
encrypted manner. Storing the phone numbers will allow for direct communication with subjects, 
including automated messaging from the Platform device and contact [CONTACT_785693]. At no time is the phone number visible to healthcare providers or 
sponsor monitoring personnel. 
Investigative site personnel will also perform compliance calculations based on returned study 
drug. Noncompliance (missed doses) or partially administered doses must be documented in the 
eCRF. 
10.4. Concomitant Medications 
Concomitant medications used within [ADDRESS_1080800] be documented on the eCRF.  
The investigator (or designee) should instruct subjects to notify the study site about any new 
medications taken after the start of the study drug and prior to study discontinuation.  
The following medication is prohibited within 12 months prior to screening and during the study: 
 Clozapi[INVESTIGATOR_785668] 30 days (90 days for fluoxetine) prior to 
screening and through the entire study period:  
 Nefazodone 
 Monoamine oxidase inhibitors such as selegiline, phenelzine, tranylcypromine 
 SSRIs and SNRIs such as fluoxetine, sertraline, escitalopram, citalopram, paroxetine, 
desvenlafaxine, duloxetine, venlafaxine 
 Tricyclic antidepressants such as amitriptyline, imipramine, nortriptyline 
 NaSSA mirtazapi[INVESTIGATOR_785669]-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 50   Serotonin modulator and stimulator antidepressants such as vilazodone or 
vortioxetine 
 Norepi[INVESTIGATOR_238], serotonin and dopamine reuptake inhibitor bupropi[INVESTIGATOR_785670] 30 days prior 
to Screening or during the study:   Other allowed antidepressants   
  
However, is 
opi[INVESTIGATOR_1649]) for at least 30 days prior to the start of screening and no change of dose occurs 
during the screening, treatment, or follow-up periods of the study.  
Medications with primarily CNS activity are prohibited within 3 days prior to screening and 
through the entire study period. Examples of these medications include the following:  
 Conventional or atypi[INVESTIGATOR_16709], anticonvulsant drugs (including 
gabapentinoids), or psychostimulants  
 Benzodiazepi[INVESTIGATOR_785671] H 1 antihistamines 
 Quetiapi[INVESTIGATOR_785672]-release  
 Other sedative-hypnotics 
Use of certain non-benzodiazepi[INVESTIGATOR_620760] (e.g., zolpi[INVESTIGATOR_620761]-release [up to 10 
mg at bedtime], zaleplon [up to 20 mg at bedtime]), melatonin, or ramelteon for sleep are 
allowed. NOTE : the non-benzodiazepi[INVESTIGATOR_785673] a single dose 
immediately before bedtime and may not be re-administered during the night.  
Use of NMDAR-binding drugs (e.g., ketamine, dextromethorphan, memantine, methadone, 
lamotrigine, esketamine) may not be used within [ADDRESS_1080801] Withdrawal Criteria (see Section 8.4). 
Clinical Protocol NYX-783-[ADDRESS_1080802] the sponsor for directions regarding non-permitted excursions. 
11.4. Study Drug Preparation 
The investigator may delegate study drug handling and accountability as appropriate. An 
interactive response technology (IRT) will specify to investigative site personnel which study 
drug kit to dispense.  
. Refer to the Product Pharmacy Manual and/or IRT manual for additional 
instruction. The pharmacy manual includes instructions for registering product complaints, if 
required. 
11.5. Study Drug Accountability 
The investigator may delegate study drug accountability as appropriate. The investigative site 
personnel will receive, inspect, acknowledge study drug condition, document amount 
received/dispensed/returned, dispense, acknowledge shipments as instructed, and maintain study 
drug accountability records. A sponsor representative will inspect the study drug and 
accountability records. Site personnel will dispense (and administer if required) study drug to 
subjects, account for and document used/unused study drug, and return any unused study drug (if 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 52  applicable) to unblinded pharmacy personnel. Only subjects enrolled in this clinical study and 
eligible to receive treatment are to receive study drug material. 
Upon completion or termination of the study, and after sponsor accountability is completed, all 
used and unused supplies must be returned or destroyed as instructed by [CONTACT_519081]. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 53  12. STUDY ASSESSMENTS  
12.1. Psychiatric Rating Scales/Outcome Measures/Test(s) 
Investigative sites will be required to identify and provide clinical raters with suitable experience 
and training to conduct interviews and/or clinician-rated scales. Remote rater qualification, 
certification, training, and surveillance will be required for all investigative site clinical raters. 
Enrollment may not begin at an investigative site until a clinical rater has been informed by [CONTACT_246221]/or designee that qualification, training, and/or certification requirements have been 
satisfied. If a clinical rater changes during the study, new rater(s) must complete qualification, 
training, and certification requirements and be deemed acceptable by [CONTACT_23638]/or designee 
prior to completing interviews and/or scales. Information from diagnostic interviews, 
medical/psychiatric and/or medication history, and rating scales may be requested by [CONTACT_785694]/or rater surveillance activities. 
12.1.1. Structured Clinical Interview for DSM-5 (SCID-5-CT) 
The Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) is a semi-
structured interview guide for making the major DSM-5 diagnoses. It is administered by a 
clinician or trained mental health professional who is familiar with DSM-5 classification and 
diagnostic criteria. ( APA 2013) 
The SCID-5-CT modules will support assessing the mental disorders-related eligibility criteria.   
12.1.2. SAFER Remote Interview 
The SAFER remote interview is an independent psychologist- or psychiatrist-administered 
interview to assess whether a subject is appropriate for a study by [CONTACT_785695]. 
The acronym stands for the  to the following criteria: State versus trait; 
Assessability; Face validity; Ecological validity; and Rule of 3 Ps (pervasive, persistent, and 
pathological). ( Desseiles 2013) The interview is intended to increase the quality of the study by 
[CONTACT_785696] a more homogenously defined PTSD population. As such, the SAFER 
interview can help in the selection of subjects who are good candidates for assessment of a 
treatment effect by [CONTACT_785697]. The SAFER interview will be completed with the subject by [CONTACT_648].   12.2. Clinical Measures 
12.2.1. Clinician Administered PTSD Scale for DSM-5 (CAPS-5) 
The CAPS-5 is a 30-item structured interview for diagnosis and assessment of PTSD ( Weathers 
2017). In addition to assessing the severity and frequency of the [ADDRESS_1080803] of symptoms on 
social and occupational functioning, improvement in symptoms since a previous CAPS-5 
interview, overall response validity, overall PTSD severity, and specifications for the 
dissociative subtype (depersonalization and derealization). CAPS-5 total symptom severity score 
is calculated by [CONTACT_572602] 20 DSM-5 PTSD symptoms. Similarly, CAPS-5 
symptom cluster severity scores are calculated by [CONTACT_785698] a given DSM-5 cluster: Criterion B, intrusions (items 1-5); 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 54  Criterion C, avoidance (items 6-7); Criterion D, negative alterations in cognitions and mood 
(items 8-14); and, Criterion E, alterations in arousal and reactivity (items 15-20). The assessor 
combines information on frequency and intensity of an item into a single severity rating (0-4) for 
each of the 20 DSM-5 PTSD symptoms, with a maximum possible score of 80 points. A higher 
score corresponds to more severe PTSD. ( APA 2013) 
12.2.2. Hospi[INVESTIGATOR_183507] (HADS) 
The HADS is a self-assessment tool consisting of two subscales, one for anxiety (HADS-A) and 
one for depression (HADS-D). ( Zigmond 1983, Bjelland 2002 ) Each subscale consists of 7 items 
that are scored from 0-3, for a maximum score of 21 for either anxiety or depression; higher 
scores represent more severe anxiety or depression.  
12.2.3. PTSD Checklist for DSM-5 (PCL-5) 
The PCL-[ADDRESS_1080804] week or month according to DSM-5 criteria. Items assess symptoms across 4 symptom 
clusters of PTSD (re-experiencing, negative mood, avoidance, and hyperarousal) on a 0-4 point 
Likert scale. Total scores range from 0-80. The should be used after 
screening. 
12.2.4. Clinical Global Impressions-Severity (CGI-S) 
The CGI-S scale assesses the global severity of illness and change in clinical condition over 
time, and subjects are rated from 1 (normal, not at all ill) to 7 (among the most extremely ill 
subjects). ( Guy 1976). 
12.2.5. Pi[INVESTIGATOR_2272] (PSQI) 
The PSQI ( Buysse 1989) is a questionnaire to assess sleep quality and disturbances over a 1-
month time interval. A total of 19 items are self-rated, 15 objective (about frequency of sleep 
disturbances and subjective sleep quality) and 4 subjective (typi[INVESTIGATOR_405187], wake-up time, sleep 
latency and sleep duration) items. These 19 items generate 7 component scores: subjective sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of 
sleepi[INVESTIGATOR_88794], and daytime dysfunction, each of which ranges from 0: no difficulty to 3: 
severe difficulty. The PSQI Global Score is generated by [CONTACT_336588] 7 individual component 
scores and ranges from 0 to 21. A global score >5 indicates significant sleep disturbance. The 
additional 5 items rated by [CONTACT_785699]. 
12.2.6. Pi[INVESTIGATOR_785663] (PSQI-A) 
The PSQI-A ( Germain 2005) is a self-report instrument to assess disruptive nocturnal behavior 
(DNB) in PTSD subjects, according to the following 7 types of behaviors:  1) hot flashes, 2) 
general nervousness, 3) memories or nightmares of traumatic experience, 4) severe anxiety or 
panic, not related to traumatic memories, 5) bad dreams, not related to traumatic memories, 6) 
epi[INVESTIGATOR_785674] 7) epi[INVESTIGATOR_785675], such as kicking, punching, running, or screaming. Each DNB is rated on a scale of 0-
3 (0: not in the past month, 1: less than once a week, 2: once or twice a week, and 3: three or 
more times a week), with a global score range of 0-21. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 55    
 
 
 
 
 
  
 
 
 
 
 
 
 
12.2.9. Dissociative Experiences Scale-II (DES-II) 
The Dissociative Experiences Scale-II (DES-II) (Carlson 1993) is a 28 item, self-report 
questionnaire that measures a wide variety of dissociative experiences, from normal (e.g., day-
dreaming) to pathological (depersonalization). Subjects rate the percentage of time they have the 
experience, from 0% to 100% (in increments of 10). 
12.2.10. Life Events Checklist for DSM-5 (LEC-5)   
The LEC-5 (Weathers 2013) is a 17-item self-reporting tool to screen 
 
12.2.11. Symbol Coding from the Brief Assessment of Cognition (BAC Symbol Coding) 
The Brief Assessment of Cognition (BACS, Keefe et al., 2004 ) is a pen-and-paper cognitive 
assessment used in hundreds of research studies and clinical trials. A tablet-based version of the 
BACS, the BAC App, was validated in 2016 to allow standardized presentation of task 
instructions and stimuli, audio-recording of responses, and automatized scoring and data 
management ( Atkins et. al., 2016). BAC Symbol Coding is delivered on the Pathway tablet and 
offers a sensitive measure of processing speed. Participants are provided a key and asked to fill 
in the corresponding numbers beneath a series of symbols as quickly as possible within 90 
seconds. The assessment takes approximately 3-5 minutes to complete, including instructions 
and practice.   
12.3. Exploratory Assessments 
  
 
 
 

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 56   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
12.4. Safety Assessments 
Refer to the Schedule of Assessments ( Table 4) or schedule of procedures section (Section 9.0) 
for time points. All abnormal or out-of-range safety results will be reviewed by [CONTACT_785700]. Possibly drug-related or clinically-relevant abnormal results of 
uncertain causality must be repeated. Ongoing abnormal findings should be followed at the 
discretion of the investigator. 
12.4.1. Demographics and Medical History 
Date of birth, sex, Hispanic ethnicity, race, smoking status, reproductive status, employment 
status, alcohol consumption, and index traumatic event will be collected. A complete medical 
and psychiatric history should include whether the subject has any significant conditions or 
diseases relevant to the condition/disease under study. The index traumatic event is the primary 
traumatic event that led to the initial development of PTSD symptoms; year of event should be 
collected. Any ongoing medical or psychiatric conditions present at the time of informed consent 
are to be documented as medical history, including clinically significant laboratory results, ECG 
findings, PE abnormalities/symptoms, or psychiatric symptoms noted during the screening 
period. The condition (i.e., diagnosis) should be described wherever possible. 
12.4.2. Vital Sign Measurements 
Each assessment includes blood pressure, respi[INVESTIGATOR_1487], heart rate (HR), and oral body 
temperature, taken after at least [ADDRESS_1080805] (seated or supi[INVESTIGATOR_050]). Height and weight will also 
be collected. Vital signs may be repeated for eligibility determination. 
12.4.3. Physical Examination (PE)  
The Investigator (or qualified designee) will perform a routine, thorough PE that includes an 
assessment of the eyes, ears, nose, throat, and extremities as well as a dermatological 

Clinical Protocol NYX-783-[ADDRESS_1080806] ECG parameters, including HR, RR, PR, 
corrected QT (QTc) intervals, and QRS duration, will be measured. 
All ECGs should be collected after at least [ADDRESS_1080807] be repeated. 
Ongoing abnormal laboratory   
All women of child-bearing potential will receive serum pregnancy tests (ß-HCG) and urine 
pregnancy tests.  
Hepatitis and HIV screen includes: HIV, hepatitis B surface antigen, and hepatitis C antibody. 
Hematology includes: White blood cell count with differential (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils); hemoglobin; hematocrit; mean corpuscular volume (MCV); 
mean corpuscular hemoglobin (MCH); MCH concentration (MCHC); mean platelet volume 
(MPV); red blood cell count; red cell distribution width (RDW), and platelet count. 
Clinical chemistry includes electrolytes (bicarbonate, calcium, chloride, phosphorus, potassium, 
sodium, magnesium), enzymes (ALP, AST, ALT, lactate dehydrogenase, gamma-glutamyl 
transferase), and other tests (albumin, bilirubin [total], direct bilirubin, indirect bilirubin, 
creatinine, glucose, protein [total], blood urea nitrogen, thyroid stimulating hormone [at 
screening only], and uric acid). 
Qualitative urinalysis includes appearance, color, pH, specific gravity, glucose, ketones, protein, 
blood, leukocyte esterase, urobilinogen, bilirubin, and nitrites. Microscopy will include red blood 
cells, white blood cells, epi[INVESTIGATOR_1663], casts, and bacteria. 
Standard blood and urine drug panel includes analysis for benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_858], cocaine, 
cannabinoids, amphetamines, barbiturates, methadone, and phencyclidine. Serum and alcohol 
breathalyzer testing will also be performed. The screening period may be extended to ensure 
washout, if needed, between screening and Day 1. 
An estimated creatinine clearance will be calculated. 
Refer to the laboratory sample collection, handling, and shippi[INVESTIGATOR_785676]. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 58  12.4.6. Sheehan Suicidality Tracking Scale (S-STS) 
The standard version of the S-STS ( Sheehan 2014[a] ) is a 16-item scale that assesses the 
seriousness of suicidality phenomena on a Likert-type scale (0 to 4) ranging from 0 = 
to . It also assesses the frequency of key phenomena and the overall time spent in 
suicidality. The standard version is available in identical clinician- and subject-rated formats. 
The tool is to be administered via interview with the subject (by a trained operator/interviewer).  
If possible, the same interviewer should be used throughout the study for the same subject.  The 
S-STS accommodates a wide range of timeframes. In clinical trials, the frequently used variants 
the past day.   
The S-STS maps to both the Columbia Suicide Severity Rating Scale ( Giddens 2014) and to all 
categories in the FDA Draft Guidance documents of both [ADDRESS_1080808] equal sensitivity to detecting suicidal ideation and behavior. ( Sheehan 2014 [b] ) 
NOTE : Suicidality identified after baseline will be recorded as an AE. 
12.5. Adverse Events and Serious Adverse Events 
12.5.1. Definition of an Adverse Event  
An AE is any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, 
disease, or laboratory or physiological observations associated with the use of an intervention in 
humans participating in a clinical study, regardless of causal relationship.  
Pre-existing conditions (i.e., ones that are present before study drug dosing) should be reported 
as an AE only if the frequency, intensity, or character of the condition worsens during the study. 
(Note: Pre-existing conditions are reported during the Screening period 
medical history.) 
Laboratory or ECG abnormalities are not considered AEs unless they are associated with clinical 
signs or symptoms or require medical intervention. However, a laboratory abnormality (e.g., a 
clinically significant change detected on clinical chemistry, coagulation, hematology, urinalysis) 
that is independent from the underlying medical condition and requires medical/surgical 
intervention or leads to study drug interruption or discontinuation, must be considered an AE. 
12.5.2. Definition of a Serious Adverse Event 
An SAE is any AE occurring at any dose that results in any of the following outcomes: 
 Death  
 
 Is a life-threatening experience  
Life-threatening AEs include any adverse drug experience, which, in the view of the 
investigator, places the subject at immediate risk of death from the reaction as it occurs. It 
Clinical Protocol NYX-783-[ADDRESS_1080809] caused 
death. 
 Requires inpatient hospi[INVESTIGATOR_785677] a persistent or significant disability/incapacity   
Disability is defined as a substantial disruption in a 
functions. 
 Results in a congenital anomaly/birth defect 
 Additionally, important medical events that may not result in death, be life threatening, or 
require hospi[INVESTIGATOR_12475], based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention 
to prevent one of the outcomes listed previously (e.g., an allergic bronchospasm requiring 
intensive treatment in an emergency room or at home). 
12.5.3. Adverse Event Reporting 
Adverse events will be collected from the time of study drug administration through the last day 
 Follow-up of AEs must be conducted in accordance 
ice.  
All AEs must be documented, evaluated, and reported in the source documents and electronic 
case report forms (eCRFs), and include the following information: duration (start and stop dates 
or if continuing at final visit), severity, relationship to study drug, action(s) taken, outcome, and 
whether it constitutes a serious adverse event (SAE). Diagnoses (rather than symptoms) should 
be recorded wherever possible. To avoid vague, ambiguous, or colloquial expressions, all AEs 
should be r  
recorded as AEs 
unless there is a clinically significant safety concern (e.g., serious adverse event). 
Subjects should be instructed to report all potential AEs to the investigator. Subjects should also 
be queried in a non-leading manner, without specific prompting (e.g.  
about all potential AEs. The site study staff should assess emerging symptoms of dissociative 
reaction similar to those caused by [CONTACT_101033], including memory impairment, 
disturbance in time, body or environmental perception, stilted speech, emotional withdrawal, 
impaired coordination, motor retardation, bizarre reasoning or illusory experiences in any 
sensory perception, or confused state; such symptoms may be captured as AEs. 
12.5.4. Serious Adverse Event Reporting 
Serious adverse event (SAE) reporting will begin from the time of informed consent and will end 
[ADDRESS_1080810] be reported to the sponsor or designee using 
the provided form either by [CONTACT_785701], 
respectively: 

Clinical Protocol NYX-783-[ADDRESS_1080811] be received within one (1) business day. 
All other SAEs or other events reportable to FDA and/or institutional review board (IRB) will be 
forwarded to the sponsor or designee within one (1) business day. 
The SAE report should provide as much of the required information as is available at the time. 
The following minimum information is required for reporting an SAE: subject identification, 
reporting source, and event outcome. Supplemental information may be transmitted using a 
follow-up report and should not delay the initial report. Aptinyx (or its authorized representative) 
may contact [CONTACT_115996]-up on the event. 
If there is any doubt whether the information constitutes an SAE, the information will be treated 
as an SAE for the purposes of this protocol.  
All relevant documentation pertaining to an SAE (additional laboratory tests, consultation 
reports, discharge summaries, postmortem reports, etc.) will be provided to the sponsor or 
designee in a timely manner. Serious AEs will be followed until resolution or return to baseline 
(when worsening of a pre-existing condition is reported). If an SAE does not return to baseline 
but reaches a stable situation that is not expected to change, this should be documented on the 
SAE form.  
12.5.5. Relationship to Study Drug 
For each reported AE/SAE, the investigator must assess the relationship to study drug using the 
following categories: 
Unrelated 
 Does not follow a known response pattern to the suspect study drug (if response pattern is 
previously known). 
 Can clearly be explained by [CONTACT_785702]. 
Unlikely Related 
 The temporal sequence from dosing of the study drug suggests that a relationship is unlikely. 
 Follows a response pattern that is unlike that of the suspect study drug (if response pattern is 
previously known). 
 r modes of therapy 
administered to the subject. 
Possibly Related 
 Follows a reasonable temporal sequence from dosing of the study drug.  
 May follow a known response pattern to the suspect study drug (if response pattern is 
previously known). 
 
administered to the subject. 
Clinical Protocol NYX-783-[ADDRESS_1080812] be assessed for severity, using the following general grading scale: 
Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy required. 
 
Moderate: Mild to moderate limitation in activity  some assistance may be needed; no or 
minimal medical intervention/therapy required. 
 
Severe: Marked limitation in activity  some assistance usually required; medical 
intervention/therapy, required hospi[INVESTIGATOR_9841]. 
 
Life-threatening: Extreme limitation in activity  significant assistance required; significant 
medical intervention/therapy required, hospi[INVESTIGATOR_27595]. 
 
When changes in the severity of an AE occur more frequently than once a day, the maximum 
severity for the experience that day should be noted. If the severity category changes over a 
number of days, then those changes should be recorded separately (with distinct onset dates). 
12.5.7. Action Taken for Adverse Events 
For each reported AE, the action taken must be evaluated and recorded on the eCRF according to 
the following criteria: 
 No action taken 
 Concomitant medication taken 
 Hospi[INVESTIGATOR_785678]-drug therapy 
 Other (specify) 
The investigator must also document on the eCRF the action taken with study drug (as a result of 
a given AE) according to the following criteria: 
 Dose not changed  
 Study drug withdrawn 
Clinical Protocol NYX-783-[ADDRESS_1080813] document the outcome according to the following 
criteria: 
 Fatal 
 Not recovered/ not resolved 
 Recovered/ resolved 
 Recovered/ resolved with sequelae 
 Recovering/ resolving 
 Unknown 
12.5.9. Other Reportable Events 
Reports of overdose (with or without an AE), abuse, dependency, inadvertent or accidental 
exposure, pregnancy, and unexpected therapeutic benefit should be forwarded in the same time 
frame as an SAE. Overdose occurs when a subject is dosed or has taken a dose greater than the 
intended or scheduled dose specified by [CONTACT_760].  
All pregnancies occurring during the study must be followed for information regarding the 
course of pregnancy, delivery, and condition of the newborn. Follow-up should be provided by 
[CONTACT_785703] a timely manner. When the newborn is healthy, further follow-
up is not necessary. Male subjects must inform the investigator if their partner becomes pregnant 
during the study. Female subjects of childbearing potential and female partners of male subjects 
must use an acceptable method of birth control during the participation in this study. 
Clinical Protocol NYX-783-[ADDRESS_1080814] 
noncompliance with study requirements. Subjects will be withdrawn from the study if any of the 
following criteria are met: 
 Occurrence of an AE, intercurrent illness, or laboratory abnormality which, in the opi[INVESTIGATOR_785679] (i.e., values are confirmed by [CONTACT_785704]) showing any 
of one following laboratory findings:   
  T   
 ALT or AST >[ADDRESS_1080815] 
   
 
upper quadrant pain, or tenderness, fever, rash, or eosinophilia (>5%) 
  
 
(msec) that was not present on the corresponding baseline ECG, or a QT/QTc interval >[ADDRESS_1080816] (DSMB) 
The sponsor or designee will appoint a Data and Safety Monitoring Board (DSMB) for the 
periodic review of available study data. The DSMB is an independent group of experts that 
advises the sponsor and the study investigators. The members of the DSMB serve in an 
individual capacity and provide their expertise and recommendations. The primary 
responsibilities of the DSMB are to (1) periodically review and evaluate the accumulated study 
data for participant safety, study conduct and progress, and (2) make recommendations to the 
sponsor concerning the continuation, modification, or termination of the trial. The DSMB 
Clinical Protocol NYX-783-[ADDRESS_1080817] 
agent, or patient population under study. The DSMB is responsible for defining its deliberative 
processes, including event triggers that would call for an unscheduled review, stoppi[INVESTIGATOR_70697], unmasking (unblinding), and voting procedures prior to initiating any data review. 
The DSMB is also responsible for maintaining the confidentiality of its internal discussions and 
activities as well as the contents of reports provided to it. Refer to the DSMB charter for 
additional details. 
 
 
 
 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 65  14. STATISTICAL METHODS 
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a statistical analysis plan (SAP), which will be finalized before study data are 
unblinded. Additional statistical analyses other than those described in this protocol may be 
performed if deemed appropriate and will be described in the SAP. 
14.1. General Principles of Statistical Analysis 
Categorical data will be summarized using counts and percentages. Continuous data will be 
summarized using descriptive statistics (number of subjects, mean, standard deviation [SD], 
median, minimum, and maximum). Unless otherwise specified, tests of treatment effects will be 
conducted using one- 10. 
14.2. Sample Size Determination 
Response to treatment will be measured using the CAPS-5 score change from baseline to Week 4 
(Stage 1) and from Week 4 to Week 8 (Stage 2). If the effect size of NYX-[ADDRESS_1080818] sizes observed in similar historical studies, this study is powered at approximately 80% to 
reject the null hypothesis at a one-sided 10 level for any single specified efficacy 
comparison. The sample size estimate assumes a 15% dropout during stage 1 and 11% dropout 
during stage 2. The sample size may be adjusted if the actual dropout rate exceeds this 
assumption.  
14.3. Analysis Populations  
Intention-to-treat (ITT):  The ITT population will consist of all randomized subjects. Subjects 
in the ITT population will be analyzed according to the treatment they are assigned at 
randomization. The primary efficacy analysis will be performed on the ITT population. Unless 
otherwise specified, all other efficacy analyses also will be conducted on the ITT population.  
Efficacy data for the 50 mg QW group will be summarized and shown in the listings but will not 
be included in the formal efficacy comparisons between treatment groups. 
NOTE: Any additional study populations for analysis of efficacy will be defined in the SAP. 
Safety Population:  The safety population consists of all randomized subjects who receive at 
least one dose of study drug (active or placebo). Subjects in the safety population will be 
analyzed according to the treatment they actually received. Unless otherwise specified, all safety 
analyses will be conducted on the Safety population. 
14.4. Analysis of Efficacy Variables 
14.4.1. Methods of Analysis 
Treatment arms [1 = placebo], [2 = NYX-783 50 mg QD], [3 = NYX-783 10 mg QD] and [7 = 
placebo], [8 = NYX-783 50 mg QD], [9 = NYX-783 10 mg QD] will be analyzed for the primary 
and secondary efficacy variables. Treatment arms [4 = placebo], [5 = NYX-783 50 mg QD], [6 = 
NYX-783 10 mg QD], [10 = placebo], and [11 = placebo] will be utilized for exploratory 
efficacy analyses to keep integrity of the trial. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 66  [IP_ADDRESS]. Primary Efficacy Endpoint Analysis 
The ITT population will be the primary efficacy analysis population. The data from the NYX-
783 treatment groups (using both Stage 1 and Stage 2) will be used for the comparison to 
placebo. This consists of subjects (randomized to placebo and NYX-783 from treatment arms 
[1], [2] and [3] for Stage 1 and treatment arms [7], [8], and [9] for Stage 2.  
will be evaluated using the weighted combination of the estimated 
treatment effects from the stage-  The 
MMRM models will include variables for treatment group, visit, treatment-by-visit interaction 
term, baseline CAPS-[ADDRESS_1080819]-squares mean (LS mean) changes 
from baseline to Week 4 (Stage 1) and from Week 4 to Week 8 (Stage 2) for the NYX-783 50 
mg QD, NYX-783 10 mg QD, and placebo groups, pooled across Stages 1 and 2 using 
Stage 1/Stage 2. 
Subgroup analyses will be conducted with visit, treatment, investigator, treatment-by-visit 
interaction, the corresponding baseline score, and the baseline-by-visit interaction  and, if 
applicable  the corresponding change from screening to baseline will be included in the model.  
[IP_ADDRESS]. Secondary Efficacy Endpoints Analyses 
The ITT population also will be utilized for analysis of the secondary efficacy endpoints. 
Analysis of change from baseline in the secondary efficacy variables, including PCL-5, HADS-
A, HADS-D, PSQI, PSQI-A, CGI-S and BAC symbol coding will use similar MMRM models to 
those used for analysis of the primary efficacy analysis, and include baseline severity score as a 
covariate. 
In addition to comparing the individual active dose groups vs. placebo, similar analyses using 
analogous models will be done using the combined QD dose groups vs. Placebo.  
  
 
 
 
 
 
 
 
 
 
 
 
 
  

Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 67  Further efficacy analysis details will be provided in the SAP. 
14.4.2. Handling of Missing Data 
analyses to support the primary efficacy analysis will be described in the SAP. 
14.4.3. Supportive Analyses 
Sensitivity analysis of the primary endpoint may be conducted using alternative weights for the 
stage-wise treatment effects. The population(s) to be evaluated in the sensitivity analysis will be 
defined in the SAP. Additional post-hoc analyses may be completed. 14.5. Subject Disposition 
The summary of subject enrollment and disposition will display the number of subjects who are 
included in each analysis population and number of subjects who completed the study vs. 
discontinued early from the study. Specific reasons for discontinuation will be summarized 
according to the reasons listed on the eCRF. All subject disposition data and analysis population 
details will be presented in the data listings. 
14.6. Demographic/Baseline Data 
14.6.1. Demographics and Other Baseline Characteristics 
Demographic and other baseline characteristic data including gender, age, height, weight, and 
BMI will be summarized using descriptive statistics. Categorical data for race and ethnicity will 
be summarized by [CONTACT_33335]. Similar descriptive statistics will be used to 
summarize the baseline clinical and other efficacy outcome characteristics. 
Treatment differences in subject 
test for categorical variables and Type III sums of squares analysis of variance (ANOVA) for 
continuous variables.  
The demographics and other baseline characteristics summaries will be provided for both the 
safety and ITT populations by [CONTACT_464410]. Data listings will be provided for all 
demographics and baseline characteristics data. 
14.6.2. Other Baseline Data 
Medical history, prior medications, and any other baseline data collected will be presented in 
separate data listings by [CONTACT_49252]. 
14.7. Study Drug Exposure 
All study drug dosing information collected on the eCRF will be summarized and presented in 
the data listings. 
14.8. Inclusion/Exclusion Criteria 
All inclusion/exclusion criteria not met will be presented in separate data listings by [CONTACT_41163]. 
Clinical Protocol NYX-783-[ADDRESS_1080820] number, study stage, and treatment assignment. 
14.10.  Analysis of Safety  
The safety population will be used for the analysis of all safety variables. 
14.10.1. Adverse Events 
Adverse events will be categorized by [CONTACT_9313] (SOC) and preferred term with the 
Medical Dictionary for Regulatory Activities. Summary tables for TEAEs will include numbers 
and percentages of subjects experiencing AEs by [CONTACT_9315]. If a subject has more 
than [ADDRESS_1080821] 
will be counted only once in that SOC category. The following summary tables will be included 
in the clinical study report for each treatment and overall: summary of AEs, relationship of AEs 
to study drug, severity of AEs, SAEs, and AEs leading to study drug discontinuation. 
Data listings will be provided for all AEs, AEs leading to study drug discontinuation, and SAEs. 
14.10.2. Clinical Laboratory Tests 
Individual results of clinical laboratory tests from hematology, serum chemistry, and urinalysis 
that are outside of the normal range will be flagged in the data listings. Results and change from 
baseline will be summarized by [CONTACT_785705]. 
Clinical laboratory data will be presented in the data listings. 
14.10.3. Electrocardiogram 
Results and change from baseline will be summarized by [CONTACT_785706] (number of subjects, mean, SD, median, minimum, and 
maximum) for each ECG parameter assessment. All ECG data will be provided in the data 
listings. 
14.10.4. Vital Sign and Weight Measurements 
Results and change from baseline will be summarized by [CONTACT_785706] (number of subjects, mean, standard deviation, median, 
minimum, and maximum) for each measurement. All vital sign and weight data will be provided 
in the data listings. 
14.10.5. S-STS 
Data collected for S-STS will be summarized by [CONTACT_21751]/time point. Change from 
baseline, if applicable, will also be calculated and summarized in the same manner. All S-STS 
data will be provided in the data listings.  
Clinical Protocol NYX-783-[ADDRESS_1080822] be maintained by [CONTACT_093](s) and 
made available for inspection by [CONTACT_3573], the FDA, and other applicable 
regulatory authorities. 
15.2. Study Monitoring 
Site visits will be conducted by [CONTACT_519094] (site monitor) to inspect 
study data, source documents, and eCRFs in accordance with International Conference for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, 
good clinical practices (GCPs), and local regulations or guidelines. The monitor will inspect the 
study data at regular intervals throughout the study to verify adherence to the protocol as well as 
completeness, consistency, and accuracy of study data. 
The investigator will permit sponsor representatives, its third-party vendors, the FDA, and/or 
respective health authorities to inspect facilities and records relevant to this study. 15.3. Case Report Forms 
An electronic CRF (eCRF) will be used to record all subject data required in this protocol. The 
eCRF must be completed by [CONTACT_222344]. The eCRF will be signed by 
[CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a sub-investigator listed on the Form FDA 1572. It is the 
responsibility of the principal investigator [INVESTIGATOR_785680] (or designee) in an accurate and timely manner. The processing of eCRFs will include 
an audit trail (to include changes made, reason for change, date of change and person making the 
change). 
15.4. Protocol Amendment(s) 
If a protocol has been filed with regulatory agencies or submitted to an IRB and requires 
changes, a protocol amendment must be written. The sponsor will make changes to the protocol. 
All amendments will be submitted to the IRB by [CONTACT_785707]. 
15.5. Audits and Inspections 
During the study, or after completion of the study, the study site may be subject to an audit by [CONTACT_785708] (or an auditor appointed by [CONTACT_785709]) and/or an inspector from the FDA and/or other regulatory authority. Every 
attempt will be made to notify the investigator in writing in advance of the audit. If the 
investigator receives notification of a regulatory inspection for a different study during the 
clinical conduct for this study, the investigator must notify the sponsor. 
Clinical Protocol NYX-783-[ADDRESS_1080823] (IRB) 
This protocol, the informed consent document, and all relevant supporting data must be 
submitted to the IRB for approval. IRB approval of the protocol, informed consent document, 
and any advertisement used to recruit study subjects must be obtained before the study may be 
initiated. The IRB must comply with requirements set forth in the Code of Federal Regulations 
(CFR) part 56. 
The investigator is responsible for keepi[INVESTIGATOR_519055], changes 
to research activity, unanticipated problems involving risk to human subjects or others, and any 
changes made to the protocol as deemed appropriate, but in any case, at least once a year. The 
investigator is also responsible for notifying the IRB of any significant AEs or protocol 
deviations that occur during the study and meet IRB reporting requirements. 
The investigator agrees that he or she will not make any changes in the research without IRB 
approval, except where necessary to eliminate apparent immediate hazards to human subjects, as 
referenced in [ADDRESS_1080824] be filed with records kept by [CONTACT_473](s). A copy of the signed informed 
consent document must be provided to the subject. If applicable, written consent will be obtained 
using a certified translation. ICF revisions must be obtained in a timely manner. 
15.9. Study File Management 
The investigator is responsible for ensuring that the study files are maintained. The study file will 
include, but is not limited to, source documents, correspondence, and regulatory documents (IRB 
approvals/correspondence, study logs, FDA 1572 forms, financial disclosures, clinical study 
material records, study drug accountability records, and medical records). 
15.10.  Study Completion 
Aptinyx requires the following data and materials be completed before a study can be considered 
terminated or completed: source documents, study drug reconciliation activities, study 
procedures and assessments are source verified. 15.11.  Confidentiality 
Personal study subject data collected and processed for the purposes of this study should be 
managed by [CONTACT_63413]/her staff with adequate precautions to ensure the 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
Aptinyx Confidential 72  confidentiality of personal health information (PHI), and in accordance with applicable national 
and/or local laws and regulations on PHI protection. 
Monitors, auditors, and other authorized agents of Aptinyx, the IRB approving this research, and 
medical records for verification of clinical study procedures and/or data, without violating the 
confidentiality of the subjects, to the extent permitted by [CONTACT_45025]. In any 
presentation of the results of this study at meetings or in publicati
remain confidential. 
15.12.  Compensation, Insurance, and Indemnity 
Information regarding compensation, insurance, and indemnity is addressed in the Clinical Trial 
Agreement. 
15.13.  Financial Disclosure 
The investigator(s) are responsible for providing financial disclosure(s) in covered clinical 
studies. Principal investigators and sub-investigators are required to disclose applicable financial 
information, and to promptly update Aptinyx with any relevant changes throughout the study and 
for 1 year after study completion. 
15.14.  Records Retention 
According to US Investigational New Drug regulations (21 CFR 312.62), records and documents 
pertaining to the conduct of this study and the distribution of study drugs including, but not 
limited to, source documents, case report forms, ICFs, clinical laboratory test results, and drug 
inventory records must be retained. These records will be kept on file by [CONTACT_1961] [INVESTIGATOR_8178] [ADDRESS_1080825]-traumatic stress disorder. Int J 
Neuropsychopharmacol. 2014;17:355-370. 
APA 2013 American Psychiatric Association. Diagnostic and Statistical Manual of 
Mental Disorders. 5th ed. American Psychiatric Publishing: Arlington, 
VA; 2013.  
Atkins 2017 Atkins, A.S., Tseng, T., Vaughan, A., Twamley, E.W., Harvey, P; 
Narasimhan, M.; Patterson, T. & Keefe, R.S.E. (2017). Validation of 
the tablet-administered Brief Assessment of Cognition (BAC Symbol 
Coding).  Schizophr Res 2017;181, 100 106. 
Baer 2013 Baer L, and Ivanova A. When should the sequential parallel 
comparison design be used in clinical trials? Clin Invest. 2013;3:823-
833. 
Banerjee 2017 Banerjee SB, Morrison FG , and Ressler KJ: Genetic approaches for the 
study of PTSD: Advances and challenges. Neurosci Lett. 2017 May 10; 
649: 139 146 
Berger 2009 Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle 
LF, Marmar CR, Figueira I. Pharmacologic alternatives to 
antidepressants in posttraumatic stress disorder: a systematic review. 
Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:169-80. 
Bjelland 2002 Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the 
Hospi[INVESTIGATOR_5620]. An updated literature review. J 
Psychosom Res. 2002;52:69-77. 
Blevins [ADDRESS_1080826] for DSM-5 (PCL-5): 
Development and Initial Psychometric Evaluation. J Trauma Stress. 
2015;28:489-498. 
Buysse [ADDRESS_1080827], Monk TH, Berman SR, Kupfer DJ. The 
Pi[INVESTIGATOR_2272]: a new instrument for psychiatric 
practice and research. Psychiatry Res. 1989;28:193-213. 
Carlson 1993 Carlson EB, Putnam FW. An update on the Dissociative Experience 
Scale. Dissociation. 1993;6:16-27. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
 76  PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 
2013;26:537-47. 
Luchkina 2018 Luchkina NV, Bolshakov VY. Mechanisms of fear learning and 
extinction: synaptic plasticity-fear memory connection. 
Psychopharmacology (Berl). 2018 Nov 10. [epub ahead of print] 
Malec 2007 Malec JF, Brown AW, Leibson CL, Flaada JT, Mandrekar JN, Diehl 
NN, Perkins PK. The Mayo Classification System for traumatic brain 
injury severity. Journal of Neurotrauma. 2007;9:1417-1424. 
Paoletti 2007 Paoletti P, Neyton J. NMDA receptor subunits: function and 
pharmacology. Curr Opin Pharmacol. 2007;7:39-47. 
Pole 2007 Pole N. The psychophysiology of posttraumatic stress disorder: a meta-
analysis. Psychol Bull. 2007;133:725-746. Radulovic 2018 Radulovic J, Ren LY, Gao C. N-Methyl D-aspartate receptor subunit 
signaling in fear extinction. Psychopharmacology (Berl). 2018 Sep 20. 
[epub ahead of print]. 
Ravindran [ADDRESS_1080828], Stein MB.  Pharmacotherapy of PTSD: premises, 
principles and priorities. Brain Res. 2009;1293:24-39. 
Samuelson 2006 Samuelson KW, Neylan TC, Metzler TJ, Lenoci M, Rothlind J, Henn-
Haase C, Choucroun G, Weiner MW. Marmar CR. Neuropsychological 
functioning in posttraumatic stress disorder and alcohol abuse. 
Neuropsychology. 2006;20:716-726. 
Sheehan 2014 [a] Sheehan DV, Giddens JM, Sheehan IS. Status update on the 
Sheehan-Suicidality Tracking Scale (S-STS) 2014. Innov Clin 
Neurosci. 2014;11(9-10):93-140. 
Sheehan 2014 [b] Sheehan DV, Alphs LD, Mao L, et al. Comparative validation of the S-
STS, the ISST-Plus, and the C-SSRS for assessing the Suicidal 
Thinking and Behavior FDA 2012 Suicidality Categories. Innov Clin 
Neurosci. 2014;11(9-10):32-46. 
Sheehan 2008 Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials 
with the discan metric of the Sheehan Disability Scale. Int Clin 
Psychopharmacol. 2008;23:70-83. 
Sherin [ADDRESS_1080829]-traumatic stress disorder: the 
neurobiological impact of psychological tramua. Dialogues Clin 
Neurosci. 2011;13:263-278. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
 77  Steckler 2012 Steckler T, Risbrough V. Pharmacological treatment of PTSD  
established and new approaches. Neuropharmacology. 2012;62(2):617-
627. 
Tamura [ADDRESS_1080830] for the 
sequential parallel design. Stat Med. 2011;30:3496-3506.  
Tsai 2016 Tsai GE. Ultimate translation: developi[INVESTIGATOR_785681] 
N-methyl-d-Aspartate receptor. Adv Pharmacol. 2016;76:257-309. 
Twamley [ADDRESS_1080831] CB, Thorp SR, Norman SB, Hami Cissell S, 
Hughes Berardi K, Grimes EM, Stein MB. Cognitive impairment and 
functioning in PTSD related to intimate partner violence. J Int 
Neuropsychol Soc. 2009;15:879-887. 
Weathers [ADDRESS_1080832] for DSM-5 (PCL-5)  LEC-5 and Extended 
Criterion A [Measurement instrument]. Version [ADDRESS_1080833] 2013. 
Available at https://www.ptsd.va.gov/professional/assessment/adult-
sr/ptsd-checklist.asp Accessed 6 December 2018.  
Weathers 2017 Weathers, FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek 
DG, Keane TM, Marx, BP. The Clinician-Administered PTSD Scale 
for DSM-5 (CAPS-5): Development and Initial Psychometric 
Evaluation in Military Veterans. Psychological Assessment 
2018;30(3):383-395. 
Utzon-Frank [ADDRESS_1080834]-traumatic stress disorder: a systematic review and 
meta-analysis of prospective studies. Scand J Work Environ Health. 
2014;40:215-229. 
Zigmond 1983 Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105]. 
Acta Psychiatr Scand. 1983;67:361-370. 
Clinical Protocol NYX-783-2004 Amendment 3 01 May 2020 
 78  17. APPENDIX A: MAYO TBI SEVERITY CLASSIFICATION 
SYSTEM 
A.  Classify as Moderate-Severe (Definite) TBI if one or more of the following criteria apply:  
1. Death due to this TBI 
2. Loss of consciousness of [ADDRESS_1080835] 24 hours <13 (unless invalidated upon 
review, e.g., attributable to intoxication, sedation, systemic shock)  
5. One or more of the following present: 
 Intracerebral hematoma 
 Subdural hematoma 
 Epi[INVESTIGATOR_785682] (dura penetrated) 
 Subarachnoid hemorrhage 
 Brain Stem injury 
B. If none of criteria A apply, classify as Mild (Probable) TBI if one or more of the following 
criteria apply: 
1. Loss of consciousness of momentary to less than [ADDRESS_1080836]-traumatic anterograde amnesia of momentary to less than 24 hours  
3. Depressed, basilar or linear skull fracture (dura intact) 
C. If none of Criteria A or B apply, classify as Symptomatic (Possible) TBI if one or more of 
the following symptoms are present: 
 Blurred vision 
 Confused (mental state changes) 
 Dazed 
 Dizziness 
 Focal neurologic symptoms 
 Headache 
 Nausea 
 
 